Main Products
Vaccine adjuvants: ▪ IA-05: a novel synthetic saponin adjuvant that has been designed to mimic the structure of the natural saponin adjuvant QS-21, but with modifications that improve its tolerability, and stability and make it more amenable to large-scale manufacturing with GMP-grade quality. ▪ IAS-01 (synthetic TLR4 and saponin): a synthetic saponin adjuvant system that contains both a synthetic TLR4 agonist and a saponin adjuvant. It is designed to be immunogenicity equivalent to the existing MPL and saponins liposome-based adjuvant product, but with improved scalability, stability, and tolerability. By combining these two adjuvants, IAS-01 is intended to enhance both the innate and adaptive immune responses to vaccines, leading to stronger and longer-lasting immunity.
Business Interests
In-/Out-Licensing, Collaborative R&D
Contact Info
Pi-Hui Liang
Acting CEO
886-2-3366-8695
phliang@ntu.edu.tw